Drug Detail

Information about Gleevec

Generic Name
Imatinib + Perifosine
IND
STI571 + KRX-0401
Brand Name (US)
Gleevec
Manufacturer
Novartis + Keryx
Drug Type
Tyrosine Kinase Inhibitor
Delivery
Oral
Approval Status
Gleevec is approved for GIST. This combination was evaluated in a phase 2 trial for GIST.
Indications
Overall Strategy
KIT Protein Based + Oncogenic Signal Path Based
Strategy
Block KIT + Block KIT Signal Path
Drug Category
KIT/PDGFRA inhibitor + AKT inhibitor

Imatinib (Gleevec) is the approved first line drug for GIST. Even in resistant GIST, it is believed that imatinib may provide control of some tumors and/or partial control of other tumors.
Perifosine is an oral inhibitor of the AKT protein. This protein is downstream in the KIT pathway. It is hoped that inhibition of AKT will provide additional antitumor effects compared to KIT inhibition alone.